Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm.
BACKGROUND
Central venous catheter (CVC)-related bloodstream infections (BSIs) are known to increase rates of morbidity and mortality in both inpatients and outpatients, including hematology-oncology patients and those undergoing hemodialysis or home infusion therapy. Biofilm-associated organisms on the lumens of these catheters have reduced susceptibility to antimicrobial chemotherapy. This study tested the efficacy of tetrasodium EDTA as a catheter lock solution on biofilms of several clinically relevant microorganisms.


METHODS
Biofilms of Staphylococcus epidermidis, methicillin-resistant S. aureus, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Candida albicans were grown to levels of approximately 1 x 10(5) colony-forming units (CFU)/cm(-1) on CVC segments in a model system, then subjected to the tetrasodium EDTA lock treatment.


RESULTS
Comparisons of biofilms before and after exposure to the 40-mg/mL(-1) tetrasodium EDTA lock for 21 hours showed that the biofilm viable cell counts of all organisms tested were significantly reduced (P < .05) after exposure to the treatment.


CONCLUSIONS
Antimicrobial lock treatment using 40 mg/mL(-1) of tetrasodium EDTA for at least 21 hours could significantly reduce or potentially eradicate CVC-associated biofilms of clinically relevant microorganisms.
Percival
Steven L
SL
Department of Microbiology, Leeds Teaching Hospitals, Leeds, United Kingdom.
Kite
Peter
P
Eastwood
Kerrie
K
Murga
Ricardo
R
Carr
Janice
J
Arduino
Matthew J
MJ
Donlan
Rodney M
RM
D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018441:Biofilms / Q000187:drug effects*; D002176:Candida albicans / Q000187:drug effects; D002405:Catheterization, Central Venous / Q000009:adverse effects; D002408:Catheters, Indwelling / Q000009:adverse effects / Q000382:microbiology*; D002452:Cell Count; D002614:Chelating Agents / Q000494:pharmacology / Q000627:therapeutic use; D003428:Cross Infection / Q000382:microbiology / Q000517:prevention & control; D004353:Drug Evaluation, Preclinical; D004492:Edetic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D004866:Equipment Contamination / Q000517:prevention & control*; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D017053:Infection Control / Q000379:methods; D007711:Klebsiella pneumoniae / Q000187:drug effects; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D008855:Microscopy, Electron, Scanning; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D018805:Sepsis / Q000382:microbiology / Q000517:prevention & control; D013010:Sonication; D013048:Specimen Handling / Q000379:methods; D013211:Staphylococcus aureus / Q000187:drug effects; D013212:Staphylococcus epidermidis / Q000187:drug effects; D013997:Time Factors
D000890:Anti-Infective Agents; D002614:Chelating Agents; D004492:Edetic Acid